Summary of Key Points Core Viewpoint - The company has decided to postpone the expected completion dates for several fundraising investment projects due to various external and internal factors affecting the investment progress, while maintaining the original investment amounts and project contents [3][6][9]. Group 1: Fundraising Overview - The company raised a total of RMB 1,098,161,380.00 from the public offering of 21,082,000 shares at a price of RMB 52.09 per share, with the funds deposited in a designated account as of May 14, 2020 [1]. - A tripartite supervision agreement was signed with the underwriting institution and a bank to manage the raised funds [1]. Group 2: Project Status and Adjustments - The company has adjusted the expected completion dates for the following projects: - "Upgrading and Expanding the Performing Arts Lighting Equipment Production Base" and "Domestic Marketing and Product Display Platform Upgrade" to December 31, 2027 - "Phase II Expansion of the Performing Arts Lighting Equipment Production Base" to December 31, 2027 [4][5]. - The total amount of funds used for these projects as of June 30, 2025, is RMB 60,165.12 million, with a total commitment of RMB 99,771.34 million [5]. Group 3: Reasons for Delay - The delay is attributed to economic adjustments, slower growth rates, and uncertainties in international trade, which have impacted the investment process and project timelines [6]. - The company has taken a cautious approach in planning the use of raised funds, considering the actual needs and market conditions [6]. Group 4: Impact of Delay - The postponement of project timelines does not alter the total investment amounts, project contents, or implementation entities, and is not expected to have a significant impact on the company's current operations [6][9]. - The board of directors and independent directors have approved the delay, affirming that it aligns with the company's development plans and regulatory requirements [8][9].

Core Viewpoint - The company has decided to postpone the expected completion date of its "Annual Production of 1.5 Million Green Ultra-Light Aluminum Alloy Wheels Smart Production Line Project" from June 30, 2025, to December 31, 2025, due to adjustments in production processes and equipment to enhance energy efficiency and automation [1][5][6]. Fundraising Overview - The company raised a total of RMB 309,999,988.14 through the issuance of 17,203,107 shares at a price of RMB 18.02 per share, with a net amount of RMB 294,031,310.98 after deducting related expenses [1][2]. - The total investment for the aluminum wheel project is RMB 190 million, with RMB 101.12 million sourced from the raised funds and RMB 39.88 million from self-raised funds [4][5]. Fund Usage Status - As of June 30, 2025, the company has utilized all raised funds, and the special account for these funds has been closed [2][4]. - The project aims to leverage local resources and enhance the company's competitiveness in lightweight components for new energy vehicles [5]. Project Delay Explanation - The delay is attributed to the need for adjustments in production technology and layout to improve energy efficiency and automation, which has led to discrepancies between planned and actual progress [5][6]. - The company assures that the delay will not affect the project's implementation quality or the intended use of the raised funds [5][6]. Impact of Delay - The postponement is deemed a prudent decision based on the project's actual construction status and will not adversely affect the company's normal operations or shareholder interests [5][6][7]. - Both the board and supervisory committee have approved the delay, confirming that it aligns with the company's strategic development and does not harm shareholder interests [6][7].

Core Viewpoint - The company, Zhejiang Weixing Industrial Development Co., Ltd., has decided to extend the construction period of its fundraising project, specifically the "Annual Production of 220 Million Meters High-end Zipper Expansion Project," by two years due to changes in the market environment and municipal planning adjustments [1][4]. Fundraising Overview - The total amount raised through the issuance of shares is 1,195.40 million yuan, with a net amount of 1,181.80 million yuan after deducting issuance costs [1]. - The funds are allocated to four projects, including the high-end zipper expansion project, a clothing accessory production project in Vietnam, and working capital supplementation [2][3]. Project Implementation Status - The high-end zipper expansion project has reached a progress of 19.38% as of June 2025, with the expected completion date adjusted to December 2028 [3]. - The project aims to produce various types of high-end zippers and will utilize existing facilities along with new construction and advanced production equipment [3]. Reasons for Delay - The delay is attributed to external factors such as the U.S. tariff war affecting global supply chains and a cautious decision-making approach from downstream brand clients due to a sluggish domestic economy [3][4]. - The company plans to enhance communication with relevant departments and monitor market dynamics during the delay period to ensure timely project completion [4]. Impact of Delay - The delay does not alter the project’s implementation entity, location, investment purpose, or total fundraising commitment, and it is expected to facilitate a more reasonable project advancement and reduce funding usage risks [4][5]. - The decision aligns with regulatory requirements and is seen as a prudent choice in light of the current economic conditions [5].

Core Viewpoint - The company has decided to extend the implementation period for its fundraising investment projects due to external factors and market conditions affecting the original timeline for project completion [1][2][6]. Fundraising Basic Information - The company issued 3,000,000 convertible bonds at a face value of RMB 100 each, raising a total of RMB 300 million, which was fully received by March 5, 2020 [1]. - The funds are allocated for projects including the "Yushui Hot Spring (Phase I) Renovation Project" [1]. Progress of Fundraising Investment Projects - As of June 30, 2025, the cumulative investment in the Yushui Hot Spring (Phase I) Renovation Project is RMB 27.95 million, with no percentage of completion reported [1]. - The current balance of the fundraising funds in various bank accounts totals approximately RMB 56.11 million [1]. Reasons for Extension of Project Implementation Period - The company aims to enhance customer experience and expand its product offerings, leading to a strategic decision to slow down the construction of the Nanshan Xiaozhai Phase II project due to challenges in the tourism industry [2][3]. - The Yushui Hot Spring (Phase I) Renovation Project has been partially initiated, but the company has decided to delay further renovations to avoid impacting current operations [3]. Measures to Ensure Timely Completion Post-Extension - The company plans to optimize project schedules, allocate resources effectively, and enhance supervision and management of the fundraising projects to ensure compliance and timely completion [4]. Re-evaluation of Fundraising Investment Projects - The Nanshan Xiaozhai Phase II project is designed to enhance the tourism offerings in the region, including a cultural square and themed hotel, which aligns with the company's strategic development plans [4][5]. Impact of Extension on Fundraising Investment Projects - The extension of the project implementation period is a prudent decision based on the current progress and does not constitute a substantive change in the project’s nature or direction [6]. Internal Decision-Making Process - The company's board of directors has approved the proposal to extend the implementation period for the fundraising investment projects [6]. Sponsor Institution's Review Opinion - The sponsor institution, CITIC Construction Investment Securities, has conducted a thorough review and found no objections to the company's decision to extend the project implementation period, confirming that it does not adversely affect shareholder interests [6].

Summary of Key Points Core Viewpoint - The company has decided to postpone the expected operational readiness date for part of its fundraising investment projects, specifically the "Chongqing Ruide Sida Optoelectronic Materials Project," from August 2025 to February 2026, based on prudent principles and current project progress [1][4]. Group 1: Fundraising Overview - The company issued 47,894,302 A-shares, raising a total of approximately 580 million RMB, with a net amount of about 568 million RMB after deducting issuance costs [1]. - The funds raised are intended for specific investment projects, including the acquisition of a 75% stake in Qingdao Hongdie New Materials Co., Ltd., and the pure manganese sulfate project [2]. Group 2: Project Delay Details - The delay in the "Chongqing Ruide Sida Optoelectronic Materials Project" is due to the need for additional time for equipment installation and debugging, as well as the completion of some ancillary works [3][4]. - The project has completed its main construction, but certain payments related to the project are pending due to contractual agreements [4]. Group 3: Impact and Compliance - The postponement of the project does not alter the project’s implementation entity, the intended use of the raised funds, or the investment scale, ensuring compliance with relevant regulations [4][5]. - The company has taken measures to ensure that the project will be completed on schedule despite the delay, including close monitoring of market changes and resource allocation [4].

Core Viewpoint - The company has decided to extend the investment timeline for certain fundraising projects, specifically the "Drug Clinical Research Project," to align with actual progress and strategic goals, without altering the project's content or financial commitments [3][6][8]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement is in place with the sponsor and the bank [1]. Investment Project Details - The company has made adjustments to its fundraising project allocations, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary [2]. - The total investment for the new project is RMB 10,905 million, with RMB 6,100 million sourced from the adjusted funds [2]. Project Timeline Adjustments - The investment period for the "Drug Clinical Research Project" has been extended by two years, now set to conclude on August 31, 2027 [6][8]. - The project includes two sub-projects: the "Vildagliptin Tablets" and "Morphine Sulfate and Naloxone Controlled-Release Capsules," with the former having completed Phase III trials [6]. Reasons for Delay - The delay is attributed to the need for additional clinical trials for the "Vildagliptin Tablets" to meet submission requirements for market approval, considering competitive market conditions and commercialization risks [6][8]. Impact of Delay - The project delay is deemed a prudent decision that will not adversely affect the company's normal operations or alter the investment's total amount, purpose, or scale [8][9]. Approval Process - The board and supervisory committee have approved the project delays, confirming that no shareholder meeting is required for this decision [8][9]. - Both the board and supervisory committee emphasize that the delay is in the best interest of shareholders and aligns with the company's long-term sustainable development [9]. Sponsor's Review - The sponsor has reviewed the project delay and found that all necessary approval procedures have been followed, with no changes to the project's financial commitments or objectives [9].

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced a two-year extension for the investment period of its "Drug Clinical Research Project" due to the actual progress of the project and to align with the company's long-term development strategy [1][4]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at a price of RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement has been signed with the sponsoring institution and the bank [1]. Investment Project Details - The company has adjusted the investment allocation for its fundraising projects, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary, Shod Pharmaceutical [2][3]. - The total investment for the "Drug Clinical Research Project" is RMB 11,400.00 million, with RMB 7,384.91 million already spent, indicating a progress rate of 64.78% [3]. Project Delay Specifics - The investment deadline for the "Drug Clinical Research Project" has been extended from September 2, 2025, to August 31, 2027, to accommodate additional clinical trials required for the project [3][4]. - The delay is attributed to the need for further clinical trials for the drug "Uroglitazone" to meet submission requirements for market approval [3][4]. Impact of Delay - The extension of the investment period is a prudent decision based on the project's actual implementation status and will not adversely affect the company's normal operations or the project's overall objectives [4][5]. - The board and supervisory committee have both approved the delay, confirming that it does not involve changes to the project's total investment, purpose, or scale [4][5].

Core Viewpoint - The company has decided to postpone the expected operational status date for the "Research and Development Center Construction Project" due to various factors affecting the project's execution timeline, ensuring that the quality of the investment is maintained and aligning with the company's long-term strategic goals [1][4]. Fundraising Project Situation - The company raised a total of RMB 467.51 million through the issuance of 34.1 million shares at a price of RMB 13.71 per share, with a net amount of RMB 408.71 million after deducting issuance costs [1]. - As of July 31, 2025, the company has allocated RMB 41.80 million to various projects, with a remaining balance of RMB 1.61 million [2][3]. Delay of Fundraising Projects - The expected operational status date for the "Research and Development Center Construction Project" has been postponed to December 31, 2026, due to delays in construction and approval processes [3][4]. - The delay is attributed to the project's location within the same building as another project, which has affected the overall timeline [3]. Impact of Delay - The postponement of the fundraising projects is deemed a prudent decision that will not adversely affect the company's operations or shareholder interests, and it complies with relevant regulations [4][5]. - The company aims to enhance the efficiency of fundraising usage and strengthen its ongoing operational capabilities through this adjustment [4]. Review Procedures and Opinions - The board of directors has approved the delay, considering it beneficial for the company's long-term development and in line with regulatory requirements [4][5]. - The sponsoring institution has confirmed that the decision followed necessary procedures and aligns with the company's business development plans [5].

Group 1 - The company, Wenzhou Yuanfei Pet Toy Co., Ltd., has announced a delay in the implementation of certain fundraising investment projects due to various factors affecting the execution timeline [1][5] - The total amount raised from the public offering was approximately 467.51 million RMB, with 34.1 million shares issued at a price of 13.71 RMB per share [1][4] - The company has established a dedicated account for the management of raised funds and signed a tripartite supervision agreement with the sponsor and the commercial bank [2][4] Group 2 - The company has adjusted the timeline for the "R&D Center Construction Project" to December 31, 2026, due to delays in construction and approval processes [5][6] - The delay is deemed necessary to enhance the efficiency of fund usage and to align with the company's long-term strategic goals [5][6] - The board of directors has approved the delay, confirming that it does not harm the interests of the company or its shareholders [6]

Group 1 - The company announced a cash dividend distribution of 0.15 yuan per share for the fiscal year 2024, approved at the annual shareholders' meeting on June 25, 2025 [2][4] - The total cash dividend distribution amounts to approximately 141.13 million yuan, based on a total share capital of 940,996,515 shares, excluding shares held in the repurchase account [4][6] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [3][4] Group 2 - The company plans to postpone the completion dates for two fundraising investment projects: the "Jixi Branch Phase III Construction Project" to August 2026 and the "Traditional Chinese Medicine Material Processing Project" to October 2026 [11][22] - The postponement is due to external environmental factors affecting project progress, and the company aims to enhance the quality of the investment projects [22][25] - The board of directors approved the postponement during the meeting held on August 11, 2025, and the decision will be submitted for approval at the upcoming shareholders' meeting [26][36] Group 3 - The company intends to provide a guarantee for its wholly-owned subsidiary, Heilongjiang Zhenbaodao Medical Trade Co., Ltd., for bank financing up to 400 million yuan [29][30] - The guarantee is deemed necessary to support the subsidiary's operational needs, with the board considering the risk to be manageable [35][36] - The total amount of external guarantees provided by the company is 1.791 billion yuan, which accounts for 22.96% of the latest audited net assets [37]